John Fuller - Concepedia

Author

John Fuller

Also Known As

Gregory M. Preston, J H Fuller, J. Ryan Fuller, John Fuller, John Fuller, Esq, John H Fuller, John H. Fuller, John Harry Fuller, Mary Flannery, Nish Chaturvedi

203

Publications

15.2K

Citations

H-Index

Concepts

All Affiliations

University College London Imperial College London The Royal Free Hospital University of Turin Maastricht University Medical Centre

About

John Fuller is an author at University College London specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	23	4K
2	Public Health	11	11	5K
3	Health Sciences	3	3	287
4	Biochemistry	2	2	84
5	Natural Sciences	1	1	34

John Fuller

Publications

14.9K

Citations

H-Index

Page 1

	Year	Citations
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington, The Lancet Metabolic SyndromePrimary PreventionDiabetes ManagementHealth PolicyCardiovascular Disease	2004	3.8K
Vascular Risk Factors and Diabetic Neuropathy Solomon Tesfaye, Nish Chaturvedi, Simon E.M Eaton, New England Journal of Medicine	2005	1.3K
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes Nish Chaturvedi, Anne-Katrin Sjolie, Judith Stephenson, The Lancet Type 1Diabetic RetinopathyHypertensionOcular DiseaseOphthalmology	1998	742
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Nish Chaturvedi, Massimo Porta, Ronald Klein, The Lancet Type 1Diabetic RetinopathyOcular DiseaseDiabetes ManagementOphthalmology	2008	449
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Anne Katrin Sjølie, Ronald Klein, Massimo Porta, The Lancet Metabolic SyndromeHypertensionDiabetic RetinopathyOcular DiseaseDiabetes Management	2008	429
The Role of Circulating Glucose and Triglyceride Concentrations and Their Interactions with Other “Risk Factors” as Determinants of Arterial Disease in Nine Diabetic Population Samples from the WHO Multinational Study Kelly M West, M. M. S. Ahuja, Peter H. Bennett, Diabetes Care HypertensionCirculating GlucoseHyperlipidemiaMinnesota-coded EkgsNational Samples	1983	410
High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K. Sabita S. Soedamah‐Muthu, John Fuller, Henrietta Mulnier, Diabetes Care	2006	386
Elevated expression of <i>axin2</i> and <i>hnkd</i> mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors Dong Yan, Marion Wiesmann, Michael Rohan, Proceedings of the National Academy of Sciences	2001	366
IL-1β mediates leptin induction during inflammation Raffaella Faggioni, Giamila Fantuzzi, John Fuller, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology	1998	301
beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Vijay Easwaran, Sang H. Lee, Landon J. Inge, PubMed Adenomatous Polyposis ColiAngiogenesisGastrointestinal OncologyMedicineCancer Cell Biology	2003	274

Page 1